Meglitinide analogues for type 2 diabetes mellitus

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes

“…Changes in qualitative measures like A1C have also been evaluated in past studies of meglitinides showing both repaglinide and meglitinides to be effective at reducing A1C values in type 2 diabetic patients. 15 When the two agents are compared we find repaglinide to have similar efficacy to sulphonyureas in A1C reduction 16 with nateglinide appearing to be slightly less efficacious. 17 Studies examining the use of repaglinide as monotherapy have shown A1C reductions up to 2.3% with fasting and postprandial reductions of 3.9 mmol/L and 6.4 mmol/L respectively.…”

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes

“…Changes in qualitative measures like A1C have also been evaluated in past studies of meglitinides showing both repaglinide and meglitinides to be effective at reducing A1C values in type 2 diabetic patients. 15 When the two agents are compared we find repaglinide to have similar efficacy to sulphonyureas in A1C reduction 16 with nateglinide appearing to be slightly less efficacious. 17 Studies examining the use of repaglinide as monotherapy have shown A1C reductions up to 2.3% with fasting and postprandial reductions of 3.9 mmol/L and 6.4 mmol/L respectively.…”

Effects of SGLT2 inhibitors on cardiovascular outcomes

“…38 Furthermore, progressive decline in β-cell dysfunction usually leads to intensification of therapy 39 with greater risks of side effects such as hypoglycaemia, weight gain, gastrointestinal disturbances and peripheral oedema. 40 The need for novel agents, with new modes of action therefore remains a clinical and public health priority and a focus of efforts in the field of drug discovery. With the majority of patients with type 2 diabetes being overweight or obese, 41 and with excess weight being a major contributor to the development of insulin resistance and impaired glucose tolerance, 42 the beneficial effects of SGLT2 inhibitors on weight will be significantly to their advantage.…”

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

“…) stimulate rapid insulin secretion from β ‐cells by inhibiting ATP‐sensitive K + channels and activating voltage‐dependent Ca 2+ channels (Table ). The extent of insulin release stimulated by meglitinides is glucose dependent and diminishes at low glucose levels . Unlike SUs, meglitinides act on a non‐SU binding site on pancreatic β ‐cells.…”

“…The extent of insulin release stimulated by meglitinides is glucose dependent and diminishes at low glucose levels. 40 Unlike SUs, meglitinides act on a non-SU binding site on pancreatic b-cells. Meglitinides are indicated as adjuncts to diet and exercise to improve glycaemic control in adults with T2DM.…”

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes

“…Changes in qualitative measures like A1C have also been evaluated in past studies of meglitinides showing both repaglinide and meglitinides to be effective at reducing A1C values in type 2 diabetic patients. 15 When the two agents are compared we find repaglinide to have similar efficacy to sulphonyureas in A1C reduction 16 with nateglinide appearing to be slightly less efficacious. 17 Studies examining the use of repaglinide as monotherapy have shown A1C reductions up to 2.3% with fasting and postprandial reductions of 3.9 mmol/L and 6.4 mmol/L respectively.…”

Effects of SGLT2 inhibitors on cardiovascular outcomes

“…38 Furthermore, progressive decline in β-cell dysfunction usually leads to intensification of therapy 39 with greater risks of side effects such as hypoglycaemia, weight gain, gastrointestinal disturbances and peripheral oedema. 40 The need for novel agents, with new modes of action therefore remains a clinical and public health priority and a focus of efforts in the field of drug discovery. With the majority of patients with type 2 diabetes being overweight or obese, 41 and with excess weight being a major contributor to the development of insulin resistance and impaired glucose tolerance, 42 the beneficial effects of SGLT2 inhibitors on weight will be significantly to their advantage.…”

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

“…) stimulate rapid insulin secretion from β ‐cells by inhibiting ATP‐sensitive K + channels and activating voltage‐dependent Ca 2+ channels (Table ). The extent of insulin release stimulated by meglitinides is glucose dependent and diminishes at low glucose levels . Unlike SUs, meglitinides act on a non‐SU binding site on pancreatic β ‐cells.…”

“…The extent of insulin release stimulated by meglitinides is glucose dependent and diminishes at low glucose levels. 40 Unlike SUs, meglitinides act on a non-SU binding site on pancreatic b-cells. Meglitinides are indicated as adjuncts to diet and exercise to improve glycaemic control in adults with T2DM.…”

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes

“…Changes in qualitative measures like A1C have also been evaluated in past studies of meglitinides showing both repaglinide and meglitinides to be effective at reducing A1C values in type 2 diabetic patients. 15 When the two agents are compared we find repaglinide to have similar efficacy to sulphonyureas in A1C reduction 16 with nateglinide appearing to be slightly less efficacious. 17 Studies examining the use of repaglinide as monotherapy have shown A1C reductions up to 2.3% with fasting and postprandial reductions of 3.9 mmol/L and 6.4 mmol/L respectively.…”

Effects of SGLT2 inhibitors on cardiovascular outcomes

“…38 Furthermore, progressive decline in β-cell dysfunction usually leads to intensification of therapy 39 with greater risks of side effects such as hypoglycaemia, weight gain, gastrointestinal disturbances and peripheral oedema. 40 The need for novel agents, with new modes of action therefore remains a clinical and public health priority and a focus of efforts in the field of drug discovery. With the majority of patients with type 2 diabetes being overweight or obese, 41 and with excess weight being a major contributor to the development of insulin resistance and impaired glucose tolerance, 42 the beneficial effects of SGLT2 inhibitors on weight will be significantly to their advantage.…”

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

“…) stimulate rapid insulin secretion from β ‐cells by inhibiting ATP‐sensitive K + channels and activating voltage‐dependent Ca 2+ channels (Table ). The extent of insulin release stimulated by meglitinides is glucose dependent and diminishes at low glucose levels . Unlike SUs, meglitinides act on a non‐SU binding site on pancreatic β ‐cells.…”

“…The extent of insulin release stimulated by meglitinides is glucose dependent and diminishes at low glucose levels. 40 Unlike SUs, meglitinides act on a non-SU binding site on pancreatic b-cells. Meglitinides are indicated as adjuncts to diet and exercise to improve glycaemic control in adults with T2DM.…”